69 related articles for article (PubMed ID: 30978414)
41. Progress in eliminating HPV-associated disease.
Stern PL; Canfell K
Papillomavirus Res; 2019 Dec; 8():100180. PubMed ID: 31425856
[No Abstract] [Full Text] [Related]
42. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
43. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
44. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
45. Cervical screening in HPV-vaccinated populations.
Canfell K
Climacteric; 2018 Jun; 21(3):227-234. PubMed ID: 29565690
[TBL] [Abstract][Full Text] [Related]
46. Primary cervical screening with high risk human papillomavirus testing: observational study.
Rebolj M; Rimmer J; Denton K; Tidy J; Mathews C; Ellis K; Smith J; Evans C; Giles T; Frew V; Tyler X; Sargent A; Parker J; Holbrook M; Hunt K; Tidbury P; Levine T; Smith D; Patnick J; Stubbs R; Moss S; Kitchener H
BMJ; 2019 Feb; 364():l240. PubMed ID: 30728133
[TBL] [Abstract][Full Text] [Related]
47. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
Landy R; Windridge P; Gillman MS; Sasieni PD
Int J Cancer; 2018 Feb; 142(4):709-718. PubMed ID: 29023748
[TBL] [Abstract][Full Text] [Related]
48. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
Simms KT; Smith MA; Lew JB; Kitchener HC; Castle PE; Canfell K
Int J Cancer; 2016 Dec; 139(12):2771-2780. PubMed ID: 27541596
[TBL] [Abstract][Full Text] [Related]
49. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
Wright TC; Stoler MH; Behrens CM; Sharma A; Zhang G; Wright TL
Gynecol Oncol; 2015 Feb; 136(2):189-97. PubMed ID: 25579108
[TBL] [Abstract][Full Text] [Related]
50. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial.
Kitchener HC; Gilham C; Sargent A; Bailey A; Albrow R; Roberts C; Desai M; Mather J; Turner A; Moss S; Peto J
Eur J Cancer; 2011 Apr; 47(6):864-71. PubMed ID: 21334200
[TBL] [Abstract][Full Text] [Related]
51. Optimising future cervical screening strategies.
Kitchener H
Papillomavirus Res; 2019 Jun; 7():201-203. PubMed ID: 30978414
[TBL] [Abstract][Full Text] [Related]
52. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]